Reformation of oxygen gradient in a disturbed sediment. by Xuegang Mao (599968)

Subjects:

Api5 depletion induces a decrease in E2F1-target gene mRNA levels without affecting E2F1 expression. by Marina Garcia-Jove Navarro (442768)

“…<p><b>A.</b> Api5 and E2F1 reciprocal regulation. After depletion of Api5 and E2F1 with specific siRNAs, H1299 cells were made quiescent by serum starvation for 48 h (0% FBS) and then allowed to progress through the cell cycle over 10 hours by FBS addition (10 h refeeding). …”

Doxorubicin (DOXO) decreases STMN1 and increases TTP in HTR-8 cells. by Xiao-Ling Ma (4179232)

Transaldolase deficiency causes a starvation-like response that decreases animal fat content and rewires lipid metabolism gene expression. by Christopher F. Bennett (3875731)

“…<b>(E)</b> RNAi knockdown of <i>tald-1</i> or <i>cco-1</i> causes a decrease in stearoyl-CoA desaturase <i>fat-7p</i>::<i>gfp</i> reporter expression. …”

<i>Kpna1</i> KO mice show decreased anxiety-like behavior in the elevated plus maze. by Koki Sakurai (11690201)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Decreased Aβ oligomer immunoreactivity in APPxPS1 mice after treatment with hNGFP61S/R100E: polyclonal pAb A11 antibody. by Simona Capsoni (161132)

Up-regulation of <i>ATP5J</i> expression enhanced cell migration and decreased 5-Fu sensitivity in DLD1 cells. by Hongbo Zhu (14981)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects: